BACKGROUND: Resistance to second-line antituberculosis drugs (SLDs) severely compromises treatment options of drug-resistant tuberculosis. We assessed the association between acquisition of resistance (AR) to second-line injectable drugs (SLIs) or fluoroquinolones (FQs) and mortality among tuberculosis cases confirmed by positive culture results with available initial and final drug susceptibility test (DST) results. METHODS: We analyzed data from the US National Tuberculosis Surveillance System, 1993-2008. Acquired resistance was defined as drug susceptibility at initial DST but resistance to the same drug at final DST. We compared survival with Kaplan-Meier curves and analyzed the association between AR and mortality using a univariate extended Cox proportional hazards model adjusted for age. RESULTS: Of 2329 cases with both initial and final DSTs to SLIs, 49 (2.1%) acquired resistance; 13 of 49 (26.5%) had treatment terminated by death compared with 222 (10.0%) of those without AR to SLIs (P < .001). Of 1187 cases with both initial and final DSTs to FQs, 32 (2.8%) acquired resistance; 12 of 32 (37.5%) had treatment terminated by death compared with 121 (10.9%) of those without AR to FQs (P = .001). Controlling for age, mortality was significantly greater among cases with AR to SLDs than among cases without AR (adjusted hazard ratio [aHR] for SLIs: 2.8; 95% confidence interval [CI],1.4-5.4; aHR for FQ: 1.9; 95% CI, 1.0-3.5). Multidrug-resistant tuberculosis at treatment initiation, positive human immunodeficiency virus status, and extrapulmonary disease were also significantly associated with mortality. CONCLUSIONS: Mortality was significantly greater among tuberculosis cases with AR to SLDs. Providers should consider AR to SLDs early in treatment, monitor DST results, and avoid premature deaths. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Resistance to second-line antituberculosis drugs (SLDs) severely compromises treatment options of drug-resistant tuberculosis. We assessed the association between acquisition of resistance (AR) to second-line injectable drugs (SLIs) or fluoroquinolones (FQs) and mortality among tuberculosis cases confirmed by positive culture results with available initial and final drug susceptibility test (DST) results. METHODS: We analyzed data from the US National Tuberculosis Surveillance System, 1993-2008. Acquired resistance was defined as drug susceptibility at initial DST but resistance to the same drug at final DST. We compared survival with Kaplan-Meier curves and analyzed the association between AR and mortality using a univariate extended Cox proportional hazards model adjusted for age. RESULTS: Of 2329 cases with both initial and final DSTs to SLIs, 49 (2.1%) acquired resistance; 13 of 49 (26.5%) had treatment terminated by death compared with 222 (10.0%) of those without AR to SLIs (P < .001). Of 1187 cases with both initial and final DSTs to FQs, 32 (2.8%) acquired resistance; 12 of 32 (37.5%) had treatment terminated by death compared with 121 (10.9%) of those without AR to FQs (P = .001). Controlling for age, mortality was significantly greater among cases with AR to SLDs than among cases without AR (adjusted hazard ratio [aHR] for SLIs: 2.8; 95% confidence interval [CI],1.4-5.4; aHR for FQ: 1.9; 95% CI, 1.0-3.5). Multidrug-resistant tuberculosis at treatment initiation, positive human immunodeficiency virus status, and extrapulmonary disease were also significantly associated with mortality. CONCLUSIONS: Mortality was significantly greater among tuberculosis cases with AR to SLDs. Providers should consider AR to SLDs early in treatment, monitor DST results, and avoid premature deaths. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Matteo Zignol; Wayne van Gemert; Dennis Falzon; Charalambos Sismanidis; Philippe Glaziou; Katherine Floyd; Mario Raviglione Journal: Bull World Health Organ Date: 2011-11-07 Impact factor: 9.408
Authors: Roque Miramontes; Lauren Lambert; Maryam B Haddad; Valerie Boaz; Stephen Hawkins; Margaret Zylstra; Rachel Allen; Sheliah Rivers; Brenda Ali; Sarah Stuart Chewning; Erin Holt; Jon Warkentin Journal: South Med J Date: 2010-09 Impact factor: 0.954
Authors: D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol Journal: Eur Respir J Date: 2011-08-04 Impact factor: 16.671
Authors: N Sarita Shah; Robert Pratt; Lori Armstrong; Valerie Robison; Kenneth G Castro; J Peter Cegielski Journal: JAMA Date: 2008-11-12 Impact factor: 56.272
Authors: Bianca R Perri; Douglas Proops; Patrick K Moonan; Sonal S Munsiff; Barry N Kreiswirth; Natalia Kurepina; Christopher Goranson; Shama D Ahuja Journal: Emerg Infect Dis Date: 2011-03 Impact factor: 6.883
Authors: J Peter Cegielski; Ekaterina Kurbatova; Martie van der Walt; Jeannette Brand; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Tracy Dalton; Carmen Contreras; Martin Yagui; Jaime Bayona; Charlotte Kvasnovsky; Vaira Leimane; Liga Kuksa; Michael P Chen; Laura E Via; Soo Hee Hwang; Melanie Wolfgang; Grigory V Volchenkov; Tatiana Somova; Sarah E Smith; Somsak Akksilp; Wanpen Wattanaamornkiet; Hee Jin Kim; Chang-Ki Kim; Boris Y Kazennyy; Tatiana Khorosheva; Kai Kliiman; Piret Viiklepp; Ruwen Jou; Angela Song-En Huang; Irina A Vasilyeva; Olga V Demikhova; Joey Lancaster; Ronel Odendaal; Lois Diem; Therese C Perez; Tarcela Gler; Kathrine Tan; Cesar Bonilla; Oswaldo Jave; Luis Asencios; Gloria Yale; Carmen Suarez; Allison Taylor Walker; Inga Norvaisha; Girts Skenders; Ingrida Sture; Vija Riekstina; Andra Cirule; Erika Sigman; Sang-Nae Cho; Ying Cai; Seokyong Eum; Jongseok Lee; Seungkyu Park; Doosoo Jeon; Isdore C Shamputa; Beverly Metchock; Tatiana Kuznetsova; Rattanawadee Akksilp; Wanlaya Sitti; Jirapan Inyapong; Elena V Kiryanova; Irina Degtyareva; Evgenia S Nemtsova; Klavdia Levina; Manfred Danilovits; Tiina Kummik; Yung-Chao Lei; Wei-Lun Huang; Vladislav V Erokhin; Larisa N Chernousova; Sofia N Andreevskaya; Elena E Larionova; Tatyana G Smirnova Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: Miranda G Loutet; Jennifer A Davidson; Tim Brown; Martin Dedicoat; H Lucy Thomas; Maeve K Lalor Journal: Emerg Infect Dis Date: 2018-03 Impact factor: 6.883